Starpharma (ASX: SPL) has received USD 3 million from AstraZeneca after the successful dosing of the first patient in the phase 1 clinical trial of AZD0466 in December 2019.
The trial took place at several sites in the US & shall recruit patients diagnosed with a range of cancers.
At AEDT 1:13 PM, SPL shares are trading 1.293% above its previous close at $1.175.
There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.
Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.
As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.